ORPHA:48736
Embryonal carcinoma of the central nervous system
Also known as: Embryonal carcinoma of the CNS
Publications
13
23.5th percentile
Trials
0
Interventional, condition-specific
Researchers
90
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0018843
- UMLS:C1333377
- NCIT:C7010
Additional Mondo synonyms (4)
central nervous system embryonal carcinoma · embryonal carcinoma of CNS · embryonal carcinoma of the CNS · embryonal carcinoma of the central nervous system
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
No specific-condition interventional trial, but broader-category trials exist — discuss eligibility with a clinician.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
13 matched papers (7 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPartial
None under the specific name; 6 for broader category embryonal carcinoma
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
13
13 papers have ever been indexed under this name. For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
13 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
7 in the last 10 years · high confidence · 23.5th percentile (publications denominator)
Phrase hits: 13 · MeSH hits: 0
Who's working on it?
90
Distinct author names in 13 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Wang S2 papers · 2023
Department of Neurosurgery, The Third Affiliated Hospital of Soochow University, Changzhou, China.
Papers in Europe PMC - 02
- 03Ahmad M1 paper · 2016
Department of Ophthalmology, New York University School of Medicine, New York, NY 10016, USA.
Papers in Europe PMC - 04
- 05Barton M1 paper · 2006Papers in Europe PMC
- 06Bernard-Gallon D1 paper · 2021
Department of Oncogenetics, Centre Jean Perrin, CBRV, 63001 Clermont-Ferrand, France.
Papers in Europe PMC - 07Bhansali A1 paper · 2016
Department of Endocrinology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
Papers in Europe PMC - 08Bignon YJ1 paper · 2021
Department of Oncogenetics, Centre Jean Perrin, CBRV, 63001 Clermont-Ferrand, France.
Papers in Europe PMC - 09Billups C1 paper · 2018
Eugene I. Hwang and Roger J. Packer, Children's National Medical Center, Washington, DC; Marcel Kool, Lukas Chavez, Sebastian Brabetz, David T.W. Jones, and Stefan M. Pfister, German Cancer Research Center; David Capper, Andreas von Deimling, and Stefan M. Pfister, University Hospital Heidelberg; Stefan M. Pfister, National Center for Tumor Diseases, Heidelberg; David Capper, Charité Medical University, Berlin, Germany; Peter C. Burger, Johns Hopkins University, Baltimore, MD; Chris Williams-Hughes, Children's Oncology Group, Littleton, CO; Catherine Billups, Yimei Li, and Amar Gajjar, St Jude Children's Research Hospital, Memphis, TN; Linda Heier, Weill Cornell Medical College, New York, NY; Alok Jaju, Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, IL; Jeff Michalski, Washington University School of Medicine, St. Louis, MO; Sarah Leary and James M. Olson, Seattle Children's Hospital and Research Institute; Sarah Leary and James M. Olson, Fred Hutchinson Cancer Research Center, Seattle, WA; Tianni Zhou, California State University, Long Beach, Long Beach, CA; Maryam Fouladi, Cincinnati Children's Hospital Medical Center, Cincinnati, OH; and Ian F. Pollack, Children's Hospital of Pittsburgh, University of Pittsburgh, Pittsburgh, PA.
Papers in Europe PMC - 10Brabetz S1 paper · 2018
Eugene I. Hwang and Roger J. Packer, Children's National Medical Center, Washington, DC; Marcel Kool, Lukas Chavez, Sebastian Brabetz, David T.W. Jones, and Stefan M. Pfister, German Cancer Research Center; David Capper, Andreas von Deimling, and Stefan M. Pfister, University Hospital Heidelberg; Stefan M. Pfister, National Center for Tumor Diseases, Heidelberg; David Capper, Charité Medical University, Berlin, Germany; Peter C. Burger, Johns Hopkins University, Baltimore, MD; Chris Williams-Hughes, Children's Oncology Group, Littleton, CO; Catherine Billups, Yimei Li, and Amar Gajjar, St Jude Children's Research Hospital, Memphis, TN; Linda Heier, Weill Cornell Medical College, New York, NY; Alok Jaju, Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, IL; Jeff Michalski, Washington University School of Medicine, St. Louis, MO; Sarah Leary and James M. Olson, Seattle Children's Hospital and Research Institute; Sarah Leary and James M. Olson, Fred Hutchinson Cancer Research Center, Seattle, WA; Tianni Zhou, California State University, Long Beach, Long Beach, CA; Maryam Fouladi, Cincinnati Children's Hospital Medical Center, Cincinnati, OH; and Ian F. Pollack, Children's Hospital of Pittsburgh, University of Pittsburgh, Pittsburgh, PA.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present). 6 trials are registered for embryonal carcinoma, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 27 July 2026
No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.
high confidence · 36.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
6 interventional trials matched embryonal carcinoma, the broader category — listed below. Those studies are not counted in the condition-specific total.
Broader category: embryonal carcinoma
6
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT04684368·RECRUITING·A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT
Conditions: Central Nervous System Nongerminomatous Germ Cell Tumor · Choriocarcinoma · Embryonal Carcinoma · Immature Teratoma·Matched via name phrase
- NCT03067181·RECRUITING·Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
Conditions: Childhood Extracranial Germ Cell Tumor · Extragonadal Embryonal Carcinoma · Germ Cell Tumor · Malignant Germ Cell Tumor·Matched via name phrase
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Embryonal carcinoma of the central nervous system" OR "Embryonal carcinoma of central nervous system" OR "Embryonal carcinoma of the CNS" OR "Embryonal carcinoma of CNS" OR "central nervous system embryonal carcinoma"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Embryonal carcinoma of the central nervous system" OR "Embryonal carcinoma of central nervous system" OR "Embryonal carcinoma of the CNS" OR "Embryonal carcinoma of CNS" OR "central nervous system embryonal carcinoma"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"embryonal carcinoma"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T00:16:27.741Z